

Korea pushes R&D of infectious disease therapeutics and vaccines

12 April 2021 | News

The International Vaccine Institute (IVI) inks MoU with Institut Pasteur Korea (IPK)

The International Vaccine Institute (IVI) and the Institut Pasteur Korea (IPK) have signed a memorandum of understanding (MOU) for mutual collaboration in the research and development of therapeutics and vaccines for infectious diseases.

Towards the shared goal of improving public health, the IPK and IVI will promote research collaboration and information exchange, holding joint workshops and seminars to connect biomedical scientists and infectious disease experts of the two organizations and their partners worldwide.

In particular, the collaboration combines IPK's research and technology in infectious disease and IVI's capabilities and know-how in developing and designing new vaccines and in supporting clinical trials to accelerate new therapeutics and vaccine development. IPK and IVI have common fields of research interest in COVID-19, MERS, Dengue, TB, etc.

The MOU signing ceremony was attended by Dr. Youngmee Jee, CEO, and Dr. Spencer Shorte, CSO from IPK, as well as Dr. Jerome Kim, Director General, and Dr. Manki Song, Deputy Director General of Science from IVI.